AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23583056
Drug: Topiramate monotherapy
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate monotherapy for ≥6 months
Trial: 21713025
Drug: Ofloxacin treatment
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ofloxacin treatment with MIC ≤0.125 µg/mL
Trial: 21713025
Drug: Ofloxacin treatment
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ofloxacin treatment with MIC between 0.25 and 0.50 µg/mL
Trial: 21713025
Drug: Ofloxacin treatment
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ofloxacin treatment with MIC 1.00 µg/mL
Trial: 21713025
Drug: Ofloxacin treatment
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ofloxacin treatment with MIC ≥0.25 µg/mL
Trial: 15542798
Drug: Vaccination with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccination with four gp100‐ and tyrosinase‐derived peptides plus low-dose IL-2 administered daily beginning day 28 (group 2)
Trial: 15542798
Drug: Vaccination with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccination with four gp100‐ and tyrosinase‐derived peptides plus low-dose IL-2 administered daily beginning day 7 (group 1)
Trial: 3949375
Drug: Diltiazem monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem monotherapy for 8 weeks
Trial: 3949375
Drug: Diltiazem therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem therapy in subjects with pretreatment glomerular filtration rates of 80 ml/min/1.73 m2 or less
Trial: 31209428
Drug: Goserelin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin with chemotherapy
Trial: 31209428
Drug: Chemotherapy without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy without goserelin
Trial: 26281052
Drug: FESS associated
RxNorm normalized name: HEPATITIS ASSOCIATED ANTIBODY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FESS associated with inferior turbinate lateral fracture and radiofrequency ablation treatment
Trial: 26281052
Drug: FESS associated
RxNorm normalized name: HEPATITIS ASSOCIATED ANTIBODY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FESS associated with inferior turbinate lateral fracture treatment
Trial: 12859126
Drug: High-quality center-based
RxNorm normalized name: COCONUT OIL 5 g in 30 mL TOPICAL OIL [High Quality Natural Rosemary]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-quality center-based care for heavier LBW infants (2,001-2,500 g) for > 400 days
Trial: 12859126
Drug: High-quality center-based
RxNorm normalized name: COCONUT OIL 5 g in 30 mL TOPICAL OIL [High Quality Natural Rosemary]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-quality center-based care for lighter LBW infants (<= 2,000 g) for > 400 days
Trial: 11063475
Drug: Behavioral intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Behavioral intervention promoting a diet providing 28% of energy from total fat, <8% from saturated fat, </=9% from polyunsaturated fat, and <0.018 mg cholesterol*kJ(‐)(1)*d(‐)(1) (not to exceed 150 mg/d)
Trial: 4036631
Drug: Nitrazepam 10
RxNorm normalized name: nitrazepam 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrazepam 10 mg (NZ)
Trial: 4036631
Drug: Temazepam 20
RxNorm normalized name: temazepam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temazepam 20 mg (TZ)
Trial: 4036631
Drug: Diazepam 5
RxNorm normalized name: diazepam 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 5 mg (DZ)
Trial: 4036631
Drug: Alprazolam 0.25
RxNorm normalized name: alprazolam 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam 0.25 mg (AZ)
Trial: 30141292
Drug: Acupuncture at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture at proximal and distal acupoints combined with NMES (20 min), oral function training (30 min), scalp acupuncture (1 h), body acupuncture (30 min), pricking blood at Jinjin and Yuye for patients of grade Ⅴ in TDS, treatment for 3 courses, 30 days, 5 times a week, once a day.
Trial: 30141292
Drug: Acupuncture at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture at proximal and distal acupoints combined with NMES (20 min), oral function training (30 min).
Trial: 30141292
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received NMES (20 min) and oral function training (30 min).
Trial: 24326812
Drug: Ankaferd Blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ankaferd Blood Stopper (ABS) - 1.0 mL administered to one half of the sockets
Trial: 24326812
Drug: Physiological serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological serum - 1.0 mL irrigated in the control half of the sockets
Trial: 12494164
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (diuretics and ACE inhibitors or ARBs)
Trial: 9922681
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of a topical and a systemic antibiotic
Trial: 9922681
Drug: Topical antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antimicrobial preparation
Trial: 2081171
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of piperacillin 30 minutes before the operation
Trial: 2081171
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g of piperacillin 30 minutes before the operation
Trial: 6781794
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of enantate testosterone and valerianate estradiol
Trial: 29813149
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral vitamin D3 supplementation of 1200 IU
Trial: 29813149
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral vitamin D3 supplementation of 400 IU
Trial: 27814853
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy protocol with emphasis on techniques of joint mobilization and soft-tissue management
Trial: 24469611
Drug: 3‐session social
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3‐session social learning and cognitive-behavioral treatment (N=100)
Trial: 22484579
Drug: Nicorandil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil (10 mg through a nasogastric tube 30 minutes before induction of anesthesia)
Trial: 19695194
Drug: Control (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (10 mL normal saline)
Trial: 8058235
Drug: Alprazolam (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (0.25 mg three times a day)
Trial: 2564011
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA, 600 mg/day)
Trial: 29596951
Drug: Gliclazide MR
RxNorm normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazide MR (60-120 mg once daily)
Trial: 22092732
Drug: 0.1% 8-methoxypsoralen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% 8-methoxypsoralen (8MOP) cream before NBUVB phototherapy
Trial: 16978159
Drug: Dexmedetomidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1 microg/kg bolus followed by 0.4 microg/kg/h infusion)
Trial: 23607215
Drug: 800 ml/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 ml/day of remaxol
Trial: 23607215
Drug: Ringer solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer solution and 10% glucose at 1:1 ratio
Trial: 12417161
Drug: Moist Exposed
RxNorm normalized name: lactose, x-ray exposed (1000 rad)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moist Exposed Burn Ointment (MEBO) application
Trial: 12621572
Drug: Topical antibiotic
RxNorm normalized name: Tetracycline and derivatives, topical antibiotics
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical antibiotic ointment application
Trial: 12621572
Drug: No topical
RxNorm normalized name: Altreno Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No topical therapy
Trial: 7697233
Drug: Aerosolized pentamidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized pentamidine (600 mg/d)
Trial: 7697233
Drug: Trimethoprim-sulfamethoxazole (TMP-SMX)
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMX) (15 mg/kg/d of trimethoprim plus 75 mg/kg/d of sulfamethoxazole)
Trial: 28117875
Drug: Topical capsaicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical capsaicin 8% (24-hour pretreatment)
Trial: 28117875
Drug: Topical capsaicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical capsaicin 8% (1-hour pretreatment)
Trial: 26003433
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy (rivaroxaban and ticagrelor)
Trial: 26003433
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (warfarin, clopidogrel, and aspirin)
Trial: 23232491
Drug: Gemcitabine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine and carboplatin with cediranib (30 mg daily)
Trial: 16704649
Drug: Infliximab 5
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab 5 mg kg(‐1) induction at weeks 0, 2 and 6 followed by maintenance every 8 weeks
Trial: 16704649
Drug: Infliximab maintenance
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab maintenance therapy
Trial: 9129564
Drug: Oral methylnaltrexone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral methylnaltrexone (19.2 mg/kg)
Trial: 9129564
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine (0.05 mg/kg)
Trial: 9129564
Drug: Oral methylnaltrexone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral methylnaltrexone (6.4 mg/kg)
Trial: 8399073
Drug: IL‐2, 9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL‐2, 9 mIU/m2/day by continuous intravenous infusion on days 1‐5, 8‐12, and 15‐19 with doxorubicin, 25 mg/m2 on day 14.
Trial: 8399073
Drug: IL‐2, 13.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL‐2, 13.5 mIU/m2/day by continuous intravenous infusion on days 1‐5, 8‐12, and 15‐19 with doxorubicin, 25 mg/m2 on day 14.
Trial: 8399073
Drug: IL‐2, 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL‐2, 18 mIU/m2/day by continuous intravenous infusion on days 1‐5 and 8‐12 with doxorubicin, 50 mg/m2 on day 7.
Trial: 8399073
Drug: IL‐2, 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL‐2, 18 mIU/m2/day by continuous intravenous infusion on days 1‐5 and 8‐12 with doxorubicin, 25 mg/m2 on day 7.
Trial: 2868549
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus dipyridamole (Persantine)
Trial: 25200049
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus placebo
Trial: 29561248
Drug: Simultaneous administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous administration of PPSV23 and QIV
Trial: 29561248
Drug: Sequential administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential administration of PPSV23 and QIV (control)
Trial: 15953576
Drug: L-arginine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (1 g/min)
Trial: 10397411
Drug: CO2 inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CO2 inhalation for 20 minutes in panicking subjects with panic disorder
Trial: 10397411
Drug: CO2 inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CO2 inhalation for 20 minutes in normal comparison subjects
Trial: 10397411
Drug: CO2 inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CO2 inhalation for 20 minutes in non-panicking panic disorder patients
Trial: 1801561
Drug: Gamma-globulin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gamma-globulin treatment
Trial: 6141186
Drug: Flutroline hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutroline hydrochloride (1, 5, 10, 20, and 100 mg daily)
Trial: 27310568
Drug: Affect-guided physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Affect-guided physical activity prescription
Trial: 27310568
Drug: Heart rate-guided
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heart rate-guided prescription
Trial: 17974109
Drug: Chemically modified
RxNorm normalized name: Chemically modified recombinant sulfamidase
DrugBank: SOBI-003 (DB15451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemically modified SLA surface implants
Trial: 17974109
Drug: Standard SLA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard SLA surface implants
Trial: 15472817
Drug: Micafungin 50
RxNorm normalized name: micafungin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micafungin 50 mg per day
Trial: 15472817
Drug: Micafungin 100
RxNorm normalized name: micafungin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micafungin 100 mg per day
Trial: 15472817
Drug: Micafungin 150
RxNorm normalized name: micafungin 150 MG in 150 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micafungin 150 mg per day
Trial: 15472817
Drug: Fluconazole 200
RxNorm normalized name: fluconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 200 mg per day
Trial: 11743140
Drug: All diets
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All diets during the oral glucose tolerance test (GTT)
Trial: 11743140
Drug: All diets
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All diets (24-hr glucose and insulin profiles)
Trial: 7843202
Drug: Subcutaneous erythropoietin
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous erythropoietin (n = 5)
Trial: 2979247
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg nocte
Trial: 2979247
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg b.d.
Trial: 2979247
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg b.d.
Trial: 26686968
Drug: Amniotic membrane
RxNorm normalized name: Amniotic Membrane Human Ophthalmic Sheet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amniotic membrane transplantation (AMT) with medical therapy (MT)
Trial: 26686968
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical therapy (MT) alone
Trial: 25291577
Drug: H7N9 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H7N9 vaccine (3.75 µg) with MF59 adjuvant
Trial: 25291577
Drug: H7N9 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H7N9 vaccine (15 µg) with MF59 adjuvant
Trial: 25291577
Drug: H7N9 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H7N9 vaccine (unadjuvanted)
Trial: 25291577
Drug: H7N9 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H7N9 vaccine (various doses)
Trial: 25291577
Drug: H7N9 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H7N9 vaccine (with adjuvant)
Trial: 20881504
Drug: NaHCO3 (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaHCO3 (0.3 g·kg‐1)
Trial: 18564953
Drug: Naturopathic Medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naturopathic Medicine (NM)
Trial: 9006584
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone replacement therapy
Trial: 8612442
Drug: Alcohol use
RxNorm normalized name: Vorvida Problematic Alcohol Use Support Software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol use > 30 g/day
Trial: 8612442
Drug: Alcohol use
RxNorm normalized name: Vorvida Problematic Alcohol Use Support Software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol use ≤ 30 g/day
Trial: 8769617
Drug: Fluconazole (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (100 mg daily)
Trial: 7033353
Drug: Sucralfate (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (4 grams in four divided doses each day)
Trial: 7033353
Drug: Cimetidine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (200 mg three times a day, 400 mg at night)
Trial: 28337719
Drug: Adherence intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adherence intervention to nebulised and inhaled antibiotics
Trial: 12211217
Drug: Orlistat with
RxNorm normalized name: Orlistat
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orlistat with selected concomitant medications (amitriptyline, atorvastatin, cyclosporine, losartan, metformin, phentermine, and sibutramine)
Trial: 12211217
Drug: Selective concomitant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective concomitant medications and orlistat
Trial: 12211217
Drug: Selective concomitant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective concomitant medications alone
Trial: 10573044
Drug: Leflunomide treatment
RxNorm normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leflunomide treatment (20 mg/d)
Trial: 10573044
Drug: Methotrexate treatment
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate treatment (7.5-15 mg/wk)
Trial: 8918487
Drug: Chemotherapy (carboplatin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (carboplatin, etoposide, and bleomycin)
Trial: 8918487
Drug: Intensified chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified chemotherapy (carboplatin, etoposide, bleomycin, and cyclophosphamide)
Trial: 8918487
Drug: Chemotherapy only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy only (without irradiation)
Trial: 8918487
Drug: Successful salvage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Successful salvage therapy
Trial: 8918487
Drug: Toxicity associated
RxNorm normalized name: HEPATITIS ASSOCIATED ANTIBODY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toxicity associated with study chemotherapy
Trial: 31691370
Drug: Dexamethasone implant
RxNorm normalized name: dexamethasone Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone implant
Trial: 24174657
Drug: Thyroid hormone
RxNorm normalized name: Thyroid hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroid hormone (TH) treatment
Trial: 20602123
Drug: Customised orthotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Customised orthotic insoles (treatment group, n = 73)
Trial: 17372175
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination of isosorbide dinitrate and hydralazine hydrochloride (FDC I/H)
Trial: 7853170
Drug: Abecarnil (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abecarnil (10, 20, 40 mg)
Trial: 7853170
Drug: Alprazolam (1.0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (1.0, 2.0, 4.0 mg)
Trial: 7853170
Drug: Alprazolam (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (high dose)
Trial: 7853170
Drug: Abecarnil (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abecarnil (high dose)
Trial: 7080851
Drug: Intramuscular haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular haloperidol decanoate injections (20 times and thereafter 15 times the optimal oral haloperidol dose)
Trial: 7080851
Drug: Intramuscular haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular haloperidol decanoate injections